Projet financé

Genetic therapy for children with Sanfilippo syndrome

Barcelona - Espagne

Sanfilippo syndrome (MPS III) is a degenerative and fatal genetic disease. Children diagnosed with MpsIII have a life expectancy between 15 and 20 years. One in every 70,000 births results on Sanfilippo syndrome.

Financé grâce à:
  • Donateurs
  • Montant total financé
    • Me quedo uno Clients 2.500€
  • Bénéficiaires directs 12

    Les personnes qui ont été naturellement bénéficiées par les actions développées dans le projet.

  • Bénéficiaires indirects 60

    Les personnes identifiables, qui reçoivent l’effet potentiel des actions menées dans le projet.

Sanfilipo Barcelona


  • Autres 2.500€
  • Total 2.500€


Sanfilippo syndrome is caused by an absence or malfunctioning of four specific enzymes essential for breaking down molecules called glycosaminoglycans (GAG).

People eliminate these substances in the urine, but they accumulate these substances in their body, especially in the brain. The substances are becoming toxic and gradually damage all cells till the death. This causes multiple effects, severe motor and mental deterioration, and premature death.


The only hope of life for children affected by Sanfilippo C, is called gene therapy, led by Drs. Bryan Bigger, University of Manchester and Dr. Alexey Pshezhetsky Montreal.

Gene therapy is largely based on direct introduction of a vector into the brain. Today it has been demonstrated the effectiveness of this therapy in the animal model (mice) improving their behavior and neuropathology.

Qui en bénéficiera ?

12 Spanish children are affected by Sanfilippo syndrome and their families.

Also the 250 families in the world who suffer from this situation.

Objectifs du projet

- A clinical trial of human gene therapy (children under 5 years).
- Demonstration of efficiency, longevity testing long-term toxicity.
- Creating HXXXXX enzyme in large quantities.

Ce site utilise des cookies. En naviguant sur notre site vous acceptez l’utilisation des cookies. En savoir plus.